Association Between Spending and Outcomes for Patients With Cancer
Menées dans un contexte américain, ces différentes études abordent les aspects économiques et financiers liés au cancer et à ses traitements, qu'il s'agisse de l'impact de la maladie sur l'emploi des personnes atteintes, des stratégies pour réduire les coûts des médicaments, du coût des programmes de prévention ou de dépistage, des difficultés financières des patients ayant survécu à la maladie, etc.
Health care spending and health outcomes vary markedly across countries and even across regions within the United States.1,2 This inevitably raises questions about whether higher spending is “worth it” in terms of better health outcomes.3-6 Regional comparisons within the United States suggest that higher health care spending—especially at the end of life (EOL)—is not associated with better health outcomes. Medicare enrollees in higher spending regions receive more care but do not seem to live longer or otherwise experience better health outcomes, although the Medicare data suggest more waste than what is seen in younger, privately insured populations.
Journal of Clinical Oncology , résumé, 2018